Patrickm Forde News Today

A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.

/PRNewswire/ -- LUNGevity Foundation, the nations leading lung cancer-focused nonprofit organization, convened a team of oncology thought leaders, the United...

A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.

Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting. Results of the randomized phase 3 CheckMate 816 trial, published simultaneously in The New England Journal of Medicine, also showed no new adverse events associated with the

email article Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed. The pCR rate increased from 2.2% with chemotherapy alone to 24.0% with the addition of nivolumab. The between-group difference increased in an analysis limited to patients who had complete resection. Clearance of circulating tumor (ct) DNA during neoadjuvant therapy in...